# MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

> **NCT02592551** · PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 24 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** MEDI4736
- **DRUG:** Tremelimumab
- **OTHER:** no other name

## Key facts

- **NCT ID:** NCT02592551
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-11
- **Primary completion:** 2019-08-06
- **Final completion:** 2022-09-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02592551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02592551, "MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02592551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*